These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 10338905)

  • 1. Review of the pharmacoeconomic research on gemcitabine in the treatment of advanced non-small cell lung cancer.
    Minshall ME; Liepa AM
    Am J Manag Care; 1998 Nov; 4(11):1591-602. PubMed ID: 10338905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic value of gemcitabine compared to cisplatin and etoposide in non-small cell lung cancer.
    Copley-Merriman C; Corral J; King K; Whiteside R; Voi M; Dorr FA; McDonald RC
    Lung Cancer; 1996 Feb; 14(1):45-61. PubMed ID: 8696720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of gemcitabine single agent therapy compared with standard treatment in stage IIIB and IV non-small cell lung cancer.
    Tennvall GR; Fernberg JO
    Med Oncol; 1998 Jul; 15(2):129-36. PubMed ID: 9789222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of gemcitabine in stage IV non-small cell lung cancer: an estimate using the Population Health Model lung cancer module.
    Evans WK
    Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-56-S7-63. PubMed ID: 9194482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healthcare outcomes: gemcitabine cost-effectiveness in the treatment of non-small cell lung cancer.
    Szczepura A
    Lung Cancer; 2002 Nov; 38 Suppl 2():S21-8. PubMed ID: 12431825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine: clinical and economic impact in inoperable non-small cell lung cancer.
    Koch P; Johnson N; van Schaik J; Andersen S; Blatter J; Bosanquet N; Copley-Merriman K; Drings P
    Anticancer Drugs; 1995 Dec; 6 Suppl 6():49-54. PubMed ID: 8718425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
    Fleeman N; Bagust A; McLeod C; Greenhalgh J; Boland A; Dundar Y; Dickson R; Tudur Smith C; Davis H; Green J; Pearson M
    Health Technol Assess; 2010 May; 14 Suppl 1():47-53. PubMed ID: 20507803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer.
    Noble S; Goa KL
    Drugs; 1997 Sep; 54(3):447-72. PubMed ID: 9279506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of single-agent gemcitabine in the treatment of non-small-cell lung cancer.
    Kelly K
    Ann Oncol; 1999; 10 Suppl 5():S53-6. PubMed ID: 10582140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of single-agent gemcitabine in advanced non-small cell lung cancer: a review.
    Hansen HH; Sørensen JB
    Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-38-S7-41. PubMed ID: 9194478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic value of gemcitabine in non-small cell lung cancer.
    Copley-Merriman C; Martin C; Johnson N; Sacristan JA; Drings PA; Bosanquet N
    Semin Oncol; 1996 Oct; 23(5 Suppl 10):90-8. PubMed ID: 8893889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
    Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE
    Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An estimate of the cost effectiveness of gemcitabine in stage IV non-small cell lung cancer.
    Evans WK
    Semin Oncol; 1996 Oct; 23(5 Suppl 10):82-9. PubMed ID: 8893888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current status and future directions of gemcitabine in the treatment of non-small cell lung cancer and pancreatic cancer].
    Yokoyama A
    Gan To Kagaku Ryoho; 2000 Jul; 27(8):1294-300. PubMed ID: 10945029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of docetaxel/gemcitabine versus docetaxel as frontline treatment of patients with advanced/metastatic non-small cell lung cancer in Greece.
    Maniadakis N; Fragoulakis V; Pallis A; Prezerakos P; Georgoulias V
    Lung Cancer; 2007 Nov; 58(2):275-81. PubMed ID: 17688969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine.
    Prendiville J; O'Brien M
    Br J Hosp Med; 1997 Apr 16-May 6; 57(8):405-9. PubMed ID: 9274666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine as single agent chemotherapy in elderly patients with stages III-IV non-small cell lung cancer (NSCLC): a phase II study.
    Bianco V; Rozzi A; Tonini G; Santini D; Magnolfi E; Vincenzi B; D'Angelillo R; Marchei P
    Anticancer Res; 2002; 22(5):3053-6. PubMed ID: 12530041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancer.
    Pimentel FL; Bhalla S; Laranjeira L; Guerreiro M
    Lung Cancer; 2006 Jun; 52(3):365-71. PubMed ID: 16650499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-agent gemcitabine in non-small cell lung cancer: the French experience.
    Le Chevalier T; Gottfried M
    Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-47-S7-49. PubMed ID: 9194480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.